S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
Authors:
Open Access
- 18 June 2014
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 25 (9) , 1743-1749
Abstract
S-1 is an oral fluoropyrimidine whose antitumor effects have been demonstrated in treating various gastrointestinal cancers, including metastatic colon cancer, when administered as monotherapy or in combination chemotherapy. We conducted a randomized phase III study investigating the efficacy of S-1 as adjuvant chemotherapy for colon cancer by evaluating its noninferiority to tegafur–uracil plus leucovorin (UFT/LV). Patients aged 20–80 years with curatively resected stage III colon cancer were randomly assigned to receive S-1 (80–120 mg/day on days 1–28 every 42 days; four courses) or UFT/LV (UFT: 300–600 mg/day and LV: 75 mg/day on days 1–28 every 35 days; five courses). The primary end point was disease-free survival (DFS) at 3 years. A total of 1518 patients (758 and 760 in the S-1 and UFT/LV group, respectively) were included in the full analysis set. The 3-year DFS rate was 75.5% and 72.5% in the S-1 and UFT/LV group, respectively. The stratified hazard ratio for DFS in the S-1 group compared with the UFT/LV group was 0.85 (95% confidence interval: 0.70–1.03), demonstrating the noninferiority of S-1 (noninferiority stratified log-rank test, P < 0.001). In the subgroup analysis, no significant interactions were identified between the major baseline characteristics and the treatment groups. Adjuvant chemotherapy using S-1 for stage III colon cancer was confirmed to be noninferior in DFS compared with UFT/LV. S-1 could be a new treatment option as adjuvant chemotherapy for colon cancer. NCT00660894.Keywords
Funding Information
- Foundation for Biomedical Research and Innovation
- Translational Research Informatics Center
- Taiho Pharmaceutical Co. Ltd.
This publication has 17 references indexed in Scilit:
- Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer TrialJournal of Clinical Oncology, 2012
- S-1 for the treatment of gastrointestinal cancerExpert Opinion on Pharmacotherapy, 2012
- Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trialBritish Journal of Cancer, 2012
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancerInternational Journal of Clinical Oncology, 2011
- From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon CancerSeminars in Oncology, 2011
- Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC)Cancer Chemotherapy and Pharmacology, 2010
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC TrialJournal of Clinical Oncology, 2009
- Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)Japanese Journal of Clinical Oncology, 2008
- Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06Journal of Clinical Oncology, 2006
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005